Cardiac amyloidosis is a condition where misfolded proteins build up in the heart muscle, making it thicker, stiffer, and less able to fill properly. Many people first hear the term after months or years of unexplained shortness of breath, swelling, fatigue, or rhythm problems—often labeled as “heart failure with preserved ejection fraction” or “hypertrophy” without a clear reason. What makes amyloidosis different is that it is not simply wear-and-tear heart disease; it is a systemic protein disorder that can affect nerves, kidneys, the digestive system, and more.
The good news is that cardiac amyloidosis is now easier to recognize than it was a decade ago, and several therapies can slow progression—especially when started early. This article walks you through the types, warning signs, testing pathway, treatment choices, and practical management steps.
Table of Contents
- What cardiac amyloidosis is and why type matters
- What causes amyloid to build up in the heart
- Symptoms, clues, and serious complications
- How cardiac amyloidosis is diagnosed
- Treatments that slow disease and relieve symptoms
- Management, prevention, and when to seek care
What cardiac amyloidosis is and why type matters
Cardiac amyloidosis happens when abnormal proteins (amyloid fibrils) deposit in the heart’s walls. These deposits act like tiny, rigid scaffolding inside the muscle, so the heart becomes less elastic. The earliest functional problem is usually diastolic dysfunction: the heart cannot relax and fill normally, leading to congestion and breathlessness even when pumping strength (ejection fraction) still looks “normal.” Over time, amyloid can also impair pumping, disrupt valves, and irritate the electrical system.
The most important concept is that cardiac amyloidosis is not one disease. Treatment depends heavily on the type:
- AL (light-chain) amyloidosis: The amyloid is made from antibody light chains produced by abnormal plasma cells in the bone marrow. AL can progress quickly and is considered a medical urgency once suspected, because heart involvement can worsen over weeks to months.
- ATTR (transthyretin) amyloidosis: The amyloid is made from transthyretin (TTR), a protein produced mainly by the liver. ATTR comes in two forms:
- ATTRv (hereditary): due to a gene variant that makes TTR unstable and more likely to misfold.
- ATTRwt (wild-type): not inherited; often develops later in life, especially in older men, and may be linked to long-term protein instability.
Why does type matter so much? Because the best therapies either stop the source protein (as in AL, by treating plasma cells) or stabilize or reduce TTR (as in ATTR). Also, the speed of progression and the risk profile differ. AL often involves multiple organs and can be rapidly life-threatening if untreated. ATTR frequently progresses more slowly but can still cause major heart failure and arrhythmias.
One more practical detail: amyloid can affect more than the heart. People often have “clues” outside cardiology—carpal tunnel syndrome, spinal stenosis, numbness in feet, kidney issues, or easy bruising. A careful clinician connects those dots and chooses the right diagnostic path so therapy starts before scarring and stiffness become permanent.
What causes amyloid to build up in the heart
Amyloid deposition is, at its core, a protein-handling problem. A normal protein either becomes abnormal (through a genetic change or instability with aging) or is produced in an abnormal form (such as light chains from a plasma cell disorder). The misfolded protein then aggregates and deposits in tissues, including the heart.
Causes by amyloidosis type
AL (light-chain) amyloidosis
- The underlying driver is usually a plasma cell dyscrasia, meaning a bone marrow population makes abnormal light chains.
- Some patients meet criteria for multiple myeloma; others have a smaller plasma cell clone but still produce enough toxic light chains to harm organs.
- In AL, the heart can be injured both by deposit formation and by direct light-chain toxicity, which helps explain why AL can deteriorate quickly.
ATTR amyloidosis
- ATTRv (hereditary): an inherited TTR gene variant makes transthyretin less stable. Instability leads to tetramer dissociation and misfolding. Different variants lean toward different patterns—some more neuropathy-heavy, others more cardiomyopathy-heavy.
- ATTRwt (wild-type): TTR is normal, but with aging, the protein can become more prone to misfolding. Many patients have a history of orthopedic issues years before heart symptoms, such as bilateral carpal tunnel syndrome, biceps tendon rupture, or lumbar spinal stenosis.
Risk factors that should raise suspicion
Cardiac amyloidosis is more likely when “common” diagnoses do not fully explain the picture. Risk is shaped by:
- Age: ATTRwt is most often recognized in older adults.
- Sex: ATTRwt is diagnosed more often in men, though women are affected too and may be under-recognized.
- Family history: cardiomyopathy, neuropathy, unexplained heart failure, or early pacemaker implantation can suggest hereditary ATTR.
- Plasma cell disorders: known monoclonal gammopathy, abnormal serum light chains, or history of myeloma raises concern for AL.
- Coexisting conditions: heart failure with preserved ejection fraction plus thickened ventricular walls, atrial fibrillation, or conduction disease—especially if blood pressure is not particularly high.
- Valve disease overlap: amyloid is more common than expected in some people with severe aortic stenosis and increased wall thickness.
A helpful framing is: amyloidosis is often “hiding” among patients who look like they have hypertensive heart disease or generic HFpEF, but the severity of thickening, the degree of diastolic impairment, and the systemic clues do not match the usual story. Recognizing risk factors early is not about labeling—it is about choosing the correct confirmatory tests and avoiding delays in disease-modifying therapy.
Symptoms, clues, and serious complications
Cardiac amyloidosis can feel frustrating because symptoms are often gradual and nonspecific at first. Many people notice a shrinking “life radius”: walking distance shortens, stairs become harder, and recovery takes longer. The key is to watch for symptom clusters that suggest restrictive physiology, arrhythmia risk, and multisystem involvement.
Common heart-related symptoms
- Shortness of breath with exertion and reduced exercise tolerance
- Swelling in legs or abdomen, rapid weight gain from fluid retention
- Fatigue that feels out of proportion to activity
- Chest pressure or discomfort (not always present, and not always typical angina)
- Palpitations from atrial fibrillation or other rhythm problems
- Lightheadedness or fainting, sometimes linked to low blood pressure, autonomic dysfunction, or conduction disease
A notable feature is that many patients have low or normal blood pressure and do not tolerate standard heart failure doses of vasodilators. If someone with “thick heart muscle” cannot tolerate blood-pressure medications and keeps worsening, amyloidosis should move up the list.
Systemic clues that often appear before the heart diagnosis
- Carpal tunnel syndrome, often on both sides, sometimes years earlier
- Lumbar spinal stenosis or biceps tendon rupture (commonly discussed in ATTRwt)
- Numbness, burning, or tingling in the feet, balance issues, or walking instability (neuropathy)
- Dizziness on standing, bowel changes, or early satiety (autonomic involvement)
- Protein in the urine or kidney dysfunction (more typical in AL)
- Easy bruising or “raccoon eyes,” enlarged tongue, or unexplained bleeding tendency (classically associated with AL)
Serious complications to recognize early
- Atrial fibrillation and atrial flutter: These can worsen symptoms quickly because a stiff ventricle depends on atrial contribution to filling. Stroke risk can be substantial, sometimes even when rhythm episodes are intermittent.
- Conduction disease: Heart block may require a pacemaker. A history of new conduction problems in a thick-walled heart is a strong clue.
- Progressive heart failure: Many patients develop recurrent congestion requiring diuretics and careful sodium management.
- Sudden deterioration: Particularly in AL, the clinical course can accelerate rapidly, with worsening shortness of breath, rising fluid needs, and low blood pressure.
When symptoms suggest urgent evaluation
Seek urgent care if there is fainting, chest discomfort at rest, new severe shortness of breath, rapid palpitations with dizziness, confusion, or rapidly worsening swelling with low urine output. In amyloidosis, waiting can turn a manageable phase into a crisis, especially when rhythm instability or low perfusion develops.
How cardiac amyloidosis is diagnosed
Diagnosis is a stepwise process designed to answer two questions: Is amyloid present in the heart? and What type is it? The second question is critical because AL and ATTR require very different treatments, and AL should be treated with urgency once suspected.
First-line clinical tests that raise suspicion
- Electrocardiogram (ECG): may show low QRS voltage, conduction delays, or pseudo-infarct patterns. A classic clue is a mismatch: very thick heart walls on imaging but relatively small ECG voltages.
- Echocardiogram: often shows increased wall thickness, diastolic dysfunction, enlarged atria, and sometimes valve thickening. Strain imaging can reveal a pattern of relative apical sparing in some cases.
- Blood tests: natriuretic peptides and troponin may be elevated, reflecting wall stress and myocardial injury, but these are not specific.
The “rule out AL first” principle
Because AL can progress quickly, clinicians typically evaluate for a monoclonal protein early, using:
- serum free light chains
- serum protein electrophoresis with immunofixation
- urine protein studies with immunofixation when needed
If these tests suggest a plasma cell disorder, the pathway often shifts toward hematology-led evaluation, and tissue typing becomes essential.
Imaging and noninvasive confirmation
For suspected ATTR, a major advance is that certain nuclear scans can strongly support ATTR cardiac amyloidosis when AL has been reasonably excluded:
- Bone-avid tracer scintigraphy (commonly discussed in clinical algorithms) can show characteristic myocardial uptake patterns. When uptake is convincing and monoclonal studies are negative, ATTR can often be diagnosed without a heart biopsy.
Additional imaging helps with staging:
- Cardiac MRI (CMR): can demonstrate tissue characteristics consistent with amyloid infiltration, such as diffuse late gadolinium enhancement and elevated extracellular volume.
- Cardiac PET may be used in select cases to evaluate alternative diagnoses or perfusion concerns.
Biopsy and amyloid typing
A biopsy may be needed when results are conflicting or when AL is likely. Tissue can come from:
- the heart (endomyocardial biopsy) when certainty is essential
- other sites (fat pad, bone marrow, kidney, or involved organs) depending on clinical context
The key is not just finding amyloid, but typing it (often using mass spectrometry or specialized immunohistochemistry) to confirm AL versus ATTR or rarer subtypes.
Genetic testing when ATTR is diagnosed
If ATTR is confirmed, clinicians often recommend genetic testing to distinguish hereditary ATTRv from wild-type ATTRwt. This matters for family counseling, screening of relatives, and therapy planning.
In practice, the best diagnostic journeys are coordinated: cardiology evaluates restrictive physiology and arrhythmia risk, while hematology and genetics clarify the protein source. Speed and accuracy matter because effective treatments are available, but they work best before the heart becomes severely stiff or rhythm complications dominate.
Treatments that slow disease and relieve symptoms
Treatment has two layers: disease-modifying therapy (aimed at the amyloid source) and supportive cardiac care (aimed at symptoms and complications). The right combination depends on whether the disease is AL or ATTR, the stage at diagnosis, and coexisting organ involvement.
Disease-modifying treatments for ATTR
ATTR therapies focus on reducing the formation of new TTR amyloid and slowing progression:
- TTR stabilizers: These drugs help keep transthyretin in a stable tetramer form, reducing misfolding. In a pivotal clinical trial, a TTR stabilizer reduced mortality and cardiovascular hospitalizations and slowed functional decline over about 30 months.
- TTR silencers (gene-silencing therapies): These reduce the liver’s production of transthyretin, lowering circulating TTR levels. Some are delivered by injection and may be considered in selected patients, particularly when neuropathy is also present or when clinical circumstances support their use.
- Emerging options: Gene-editing and next-generation stabilizers and silencers are under study and may expand future choices.
Treatment selection is individualized based on symptoms (often framed by functional class), kidney function, neuropathy status, access, and tolerance.
Disease-modifying treatments for AL
AL amyloidosis is treated by targeting the plasma cell clone producing toxic light chains:
- Combination chemotherapy regimens are often used, selected and dosed carefully because cardiac involvement increases treatment risk.
- Monoclonal antibody therapy may be added in many cases to deepen and speed the hematologic response.
- Stem cell transplant is appropriate for a subset of patients, but significant cardiac involvement can limit eligibility; decisions are made by specialized teams.
In AL, the immediate goal is a rapid reduction in circulating light chains, because that can stabilize organ function and improve outcomes.
Supportive cardiac care that often differs from typical heart failure
Because amyloid hearts are stiff and sensitive to blood pressure changes, supportive care is often built around:
- Diuretics as the backbone for fluid control, adjusted carefully to avoid kidney injury and low blood pressure.
- Caution with standard heart failure drugs: ACE inhibitors, ARBs, and beta-blockers may be poorly tolerated in some patients, especially with low baseline blood pressure or conduction disease.
- Arrhythmia management: atrial fibrillation is common; rhythm control strategies, rate control choices, and anticoagulation are individualized.
- Device therapy: pacemakers are used for conduction disease; defibrillators may be considered in selected cases, though the decision can be complex and depends on arrhythmia mechanism and overall prognosis.
Advanced therapies in select patients
In carefully selected scenarios, organ transplantation can be considered:
- Heart transplant may be an option for some patients with advanced cardiac involvement, followed by ongoing disease-specific therapy (for example, controlling AL source or using ATTR-directed treatment).
- Combined organ strategies may be discussed in certain hereditary ATTR contexts, though modern TTR-lowering treatments have changed the landscape.
The central theme is precision: treat the protein source with the right disease-modifying therapy, and treat the heart with a plan designed for restrictive physiology rather than standard cardiomyopathy routines.
Management, prevention, and when to seek care
Living with cardiac amyloidosis often means managing a chronic condition with clear priorities: maintain stable fluid balance, protect rhythm and conduction, reduce progression with disease-specific therapy, and monitor organ systems that amyloid can affect. Many patients do best with a coordinated care team that includes cardiology plus hematology or genetics, depending on amyloid type.
Day-to-day management habits that make a real difference
- Fluid and sodium strategy: Many patients need a consistent sodium limit and a plan for fluid intake that matches diuretic needs. The goal is steady, not swinging between overload and dehydration.
- Daily weight monitoring: A gain of 1–2 kg over a few days can signal early congestion. Catching it early may prevent hospitalization.
- Blood pressure and dizziness tracking: Record seated and standing symptoms. Orthostatic dizziness can reflect autonomic involvement, over-diuresis, or medication effects.
- Medication review discipline: Because tolerance is variable, avoid self-adjusting heart medications without guidance. Bring a complete medication list to every visit, including supplements.
Managing rhythm risk proactively
Atrial fibrillation is common and can drive sudden decline. Practical steps include:
- reporting palpitations, abrupt fatigue, or reduced exercise capacity early
- discussing an individualized anticoagulation plan if atrial fibrillation occurs, since stroke risk can be meaningful
- monitoring for conduction disease signs such as near-syncope, very slow pulse, or unexplained falls
Family and prevention considerations
- If hereditary ATTR is diagnosed: relatives may be offered genetic counseling and, if appropriate, targeted testing and screening. Earlier awareness can prevent years of unexplained symptoms and allow earlier therapy.
- If AL is diagnosed: ongoing monitoring focuses on hematologic response and recurrence risk, even if heart symptoms improve.
What follow-up often includes
A structured follow-up plan may involve:
- symptom review focused on congestion and exercise capacity
- labs for kidney function and electrolytes (especially with diuretics)
- rhythm monitoring when symptoms suggest intermittent arrhythmia
- periodic imaging to assess heart structure and function
- tracking disease-modifying therapy response (light-chain markers in AL, clinical and imaging markers in ATTR)
When to seek urgent care
Seek emergency evaluation for:
- fainting or near-fainting, especially if new
- shortness of breath at rest or rapidly worsening swelling
- chest pressure at rest or severe new chest discomfort
- rapid or irregular heartbeat with dizziness or weakness
- confusion, very low urine output, or inability to keep fluids down
Cardiac amyloidosis is increasingly treatable, but it remains serious. The most protective strategy is early diagnosis, consistent disease-modifying therapy, and a management plan that respects how a stiff, amyloid-infiltrated heart responds differently to medications, fluid shifts, and rhythm changes.
References
- 2023 ACC Expert Consensus Decision Pathway on Comprehensive Multidisciplinary Care for the Patient With Cardiac Amyloidosis: A Report of the American College of Cardiology Solution Set Oversight Committee 2023 (Guideline)
- Diagnosis and treatment of cardiac amyloidosis: a position statement of the ESC Working Group on Myocardial and Pericardial Diseases 2021 (Guideline)
- 2024 Australia-New Zealand Expert Consensus Statement on Cardiac Amyloidosis 2024 (Guideline)
- Tafamidis Treatment for Patients with Transthyretin Amyloid Cardiomyopathy 2018 (RCT)
Disclaimer
This article is for educational purposes and does not provide medical advice, diagnosis, or treatment. Cardiac amyloidosis is a serious condition that can progress and can be associated with arrhythmias, fainting, and heart failure. If you have chest pressure at rest, fainting, sudden or severe shortness of breath, rapidly worsening swelling, confusion, or a fast or irregular heartbeat with dizziness, seek emergency care immediately. For personalized decisions about testing, medications, chemotherapy, transthyretin-directed therapy, anticoagulation, and device options, consult your cardiologist, transplant or amyloidosis specialist, or a qualified clinician who can review your full medical history and results.
If you found this article helpful, please share it on Facebook, X (formerly Twitter), or any platform you prefer, and follow us on social media. Your support through sharing helps our team continue producing quality content.
